Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in rheumatic disease (2 arms), sponsored by NYU Langone Health. Primary endpoints: Incidence of wound complications at 90 days, Incidence of superficial surgical site infections at 90 days and 3 more. Started Dec 2025; status: recruiting.
02
Conditions
rheumatic disease
Beyond the preview
Go deeper on NCT07138898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138898.